In connection with its Q3 business review, Bioretec shed light on its situation and the commercial challenges of the RemeOs product family. The company is seeking new commercial momentum through recruitment and revisions to its distribution model. Further, the company is preparing a strategy update, which is to be launched by the end of the year. Bioretec's CEO Sarah Hubar-Fisher in an interview with analyst Antti Siltanen.

Topics:

00:00 Introduction

00:12 H1 figures revisions

01:20 Summary of the third quarter

02:34 Gross profit

03:51 Status of the RemeOs launch in Europe

04:48 Reasons for the distribution model revision

07:23 Increased headcount

09:05 Change negotiations

10:30 Targets and strategy update

11:39 Timeline for clinical trial

12:32 Screw model approvals and indication expansions in the US

13:23 Cash runway

14:08 Turning the cash flow positive

14:45 Outlook for the rest of the year and 2026